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1. “The Great Infection of Mankind”
The World Health Organization (WHO) estimates that 
approximately two billion people worldwide are infected 
with the soil-transmitted nematode helminths Ascaris 
lumbricoides, Trichuris trichirua, and the hookworms Neca-
tor americanus and Ancylostoma duodenale. Approximately 
400 million of these infected individuals are children of 
school age and 300 million suffer from heavy worm bur-
dens sufficient to result in severe disease. Overall, it is be-
lieved that, together with schistosomiasis, the soil-trans-
mitted helminth infections account for 40% of the global 
morbidity caused by all infectious diseases, exclusive of 
malaria (WHO, 2000).
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Abstract
Hookworm infection is one of the most important parasitic infections of humans, possibly outranked only by malaria as a cause of 
misery and suffering. An estimated 1.2 billion people are infected with hookworm in areas of rural poverty in the tropics and sub-
tropics. Epidemiological data collected in China, Southeast Asia, and Brazil indicate that, unlike other soil-transmitted helminth 
infections, the highest hookworm burdens typically occur in adult populations, including the elderly. Emerging data on the host 
cellular immune responses of chronically infected populations suggest that hookworms induce a state of host anergy and immune 
hyporesponsiveness. These features account for the high rates of hookworm reinfection following treatment with anthelminthic 
drugs and therefore, the failure of anthelminthics to control hookworm. Despite the inability of the human host to develop natu-
rally acquired immune responses to hookworm, there is evidence for the feasibility of developing a vaccine based on the successes 
of immunizing laboratory animals with either attenuated larval vaccines or antigens extracted from the alimentary canal of adult 
blood-feeding stages. The major antigens associated with each of these larval and adult hookworm vaccines have been cloned and 
expressed in prokaryotic and eukaryotic systems. However, only eukaryotic expression systems (e.g., yeast, baculovirus, and in-
sect cells) produce recombinant proteins that immunologically resemble the corresponding native antigens. A challenge for vac-
cinologists is to formulate selected eukaryotic antigens with appropriate adjuvants in order to elicit high antibody titers. In some 
cases, antigen-specific IgE responses are required to mediate protection. Another challenge will be to produce anti-hookworm 
vaccine antigens at high yield low cost suitable for immunizing large impoverished populations living in the developing nations 
of the tropics.
Keywords: Hookworm; Necator, Ancylostoma, vaccines, recombinant proteins, expression systems
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Because they injure their human hosts directly by caus-
ing intestinal blood loss leading to iron deficiency and 
protein malnutrition, some investigators implicate hook-
worms as the most important helminthic cause of global 
disease burden. Professor Norman Stoll of the Rocke-
feller Institute and Foundation considered hookworms 
“The Great Infection of Mankind” (Stoll, 1962), second 
only to malaria as the major cause of human misery in the 
tropics.
Despite its global importance hookworm has, until re-
cently, been overlooked as a public health problem. There 
are several reasons for this situation. Among them, hook-
worm disease and anemia, which result from parasite-
induced blood loss are frequently insidious and seldom 
dramatic in their clinical presentation; they are not usu-
ally associated directly with high mortality. Therefore, 
clinical experts often fail to link human hookworm infec-
tion to a significant cause of morbidity worldwide. More-
over, because of the misconception that hookworm could 
be prevented by increased use of shoes in tropical coun-
tries, hookworm was often not deemed worthy of scien-
tific study. Possibly for these reasons, hookworm was 
not listed as one of the six major tropical infections of the 
Tropical Disease Research (TDR) program established by 
the WHO during the 1980s (Hotez et al., in press).
Our ignorance regarding the public health importance 
of hookworm began to change during the early 1990s 
when new quantitative estimates of disease burden based 
on the concept of disability adjusted life years (DALYs) 
revealed hookworm’s global impact (Murray and Lo-
pez, 1996). DALY estimates determined that the disease 
burden from hookworms exceeds three tropical infec-
tious diseases under investigation in the WHO-TDR pro-
gram: African trypanosomiasis, Chagas disease, and lep-
rosy. Hookworm was also found to outrank dengue fever 
(Murray and Lopez, 1996).
More recent DALY estimates for the global burden 
of disease in 2001 indicate that hookworms cause even 
greater disease burden than previously believed (WHO, 
2002). Hookworm exceeds conditions such as schistoso-
miasis and both hepatitis B and C. New data on the ep-
idemiology of iron deficiency anemia in East Africa in-
dicate that hookworm accounts for a large percentage 
of the huge DALY estimates resulting from this condi-
tion (Stoltzfus et al., 1997a; Stoltzfus et al., 1997b; Drey-
fuss et al., 2000). Iron deficiency anemia currently ac-
counts for a higher percentage of DALYs than HIV-AIDS 
and is almost as important as malaria! Hookworm-asso-
ciated iron deficiency has been noted to be particularly 
common in coastal communities in the tropics (Lwambo 
et al., 1991). The observation that hookworm anemia oc-
curs in an estimated 44 million women in pregnancy with 
resultant health consequences for the fetus and newborn 
(Bundy et al., 1995), will likely add to these disease bur-
den estimates.
Newer findings that hookworms may induce a state of 
host immunological hyporesponsiveness (see below) and 
could promote susceptibility to intercurrent viral, bacte-
rial or protozoan infections such as measles, HIV-AIDS 
(Borkow et al., 2000; Wolday et al., 2002) and tuberculo-
sis (Borkow and Bentwich, 2000; Borkow et al., 2001) have 
tremendous importance in areas where these diseases 
overlap. High rates of hookworm are known to occur in 
Subsaharan Africa (Albonico et al., 1995; Behnke et al., 
2000; Bradley et al., 1993; Brooker et al., 2000a; Brooker et 
al., 2000b; Lwambo et al., 1999; Palmer and Bundy, 1995; 
Partnership for Child Development, 1998; Stoltzfus et 
al., 2001; Stephenson et al., 1989), South China (Hotez et 
al., 1997; Liu et al., 1999; Zhan et al., 2000; Gandhi et al., 
2001; Bethony et al., 2002; Hotez, 2002), Southeast Asia 
(Humphries et al., 1997), India and Nepal (Haswell-El-
kins et al., 1988; Dreyfuss et al., 2000), and in the Ameri-
cas (Bloch and Rivera, 1977; Labiano-Abello et al., 1999). 
In each of these regions HIV-AIDS is spreading rapidly. 
Therefore, a firm link between hookworm and HIV-AIDS 
would forever alter our concept of the importance of 
hookworm as a cause of global disease burden.
2. The emerging epidemiology of hookworm
Traditionally, the epidemiology of hookworm has 
been considered to be much like other soil-transmitted 
helminth infections, such as ascariasis and trichuriasis, 
i.e., an infection in which the heaviest worm burdens oc-
cur in children of school age (Bundy, 1990). Indeed, the 
clinical effects of pediatric hookworm anemia are well de-
scribed in the literature (Hotez, 1989), including physical, 
mental and cognitive growth retardation effects (Smilie 
and Augustine, 1926; Hotez, 1989; Sakti et al., 1999; Beas-
ley et al., 2002; Lwambo et al., 2000; Hotez, 2000; Stoltzfus 
et al., 2001).
While heavy hookworm burdens still occur among 
children in some tropical areas (Stephenson et al., 1989; 
Labiano-Abello et al., 1999), studies conducted worldwide 
within the last decade indicate that the peak prevalence 
and infection intensities for hookworm often occur in in-
dividuals in middle age, or even the elderly (Gandhi et 
al., 2001; Bethony et al., 2002). Shown in Figure 1 are the 
relationships between age and prevalence or age and in-
tensity of hookworm in two different helminth-endemic 
regions of China (Hainan Province) and Brazil (Minas 
Gerias State). These represent areas of high hookworm 
transmission and endemicity (Gandhi et al., 2001; Bethony 
et al., 2002), and demonstrate that both prevalence and in-
tensity increase as a function of age. Especially striking 
is the strong correlation (r = 0.69; P < 0.001) between age 
and egg counts shown in Hainan. In the Hainan study, a 
variance components analysis revealed that age and gen-
der made the most important contributions to infection 
intensity (28–30%), with age alone responsible for 27% 
of this variation (Bethony et al., 2002). Figure 2 compares 
the age-related intensities of hookworm infections in both 
Hainan and Minas Gerias with other endemic helminth 
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infections. In Hainan, Ascaris and Trichuris infections de-
crease after the age of 20, while in Minas Gerias the inten-
sity of schistosomiasis diminishes after the age of 10. This 
is in distinct contrast to hookworm epidemiologic pat-
terns. Similar patterns for infection have been observed in 
other N. americanus endemic areas (Liu et al., 1999; Wang 
et al., 1999; Zhan et al., 2000; Humphries et al., 1997).
The association between increasing age and increasing 
prevalence and hookworm burden reveals an important 
public health problem for developing countries, since the 
elderly are seldom mentioned as a group either at high-
risk for infection or the consequent morbidity associated 
with high worm burdens. The influence of aging on the 
prevalence and intensity of Necator infection has impor-
tant public health consequences. In some parts of the de-
veloping world, such as China, the elderly are one of the 
most rapidly expanding age groups (Hotez, 2002).
The mechanisms by which hookworms establish 
chronic infections among the middle-aged and elderly are 
under active investigation. Increasing evidence suggests 
that this phenomenon may have an immunologic basis. In 
Papua New Guinea, Quinnell et al. (1993, 1995) observed 
Figure 1. The prevalence and intensity of infection with Necator americanus increases with age in two endemic areas: Hainan Province, People’s Re-
public of China (1999) and Minas Gerias, Brazil (2000). Data are from cross-sectional studies. Analysis of variance showed that egg counts were 
significantly different (P < 0.001) among the age intervals, and that the eldest four age intervals were significantly different (P < 0.05) from the 
younger age intervals, but not different from each other. 
Figure 2. The age distribution of Necator americanus differs from other soil-transmitted helminths such as Ascaris lumbricoides, Trichuris trichiura, 
as well as Schistosoma mansoni. Panel A shows the relationship between age and infection intensity for three STHs in a cross-sectional study from 
Hainan, People’s Republic of China. Ascaris lumbricoides and Trichuris trichiura epgs peak among children and then decline into adulthood. The 
intensity of infection with Necator americanus increases with age, peaking in eldest age category (80+). Panel B shows the distribution for Neca-
tor americanus in relation to other helminth infections, from Minas Gerais, Brazil. The distribution of Schistosoma mansoni infection intensity shows 
a traditional convex curve with age, increasing dramatically in young adults. The intensity of infection with Necator americanus again increases 
steadily with age, peaking in the eldest age categories. 
1248 Ho t e z e t a l .  i n  In t e r n a t I o n a l Jo u r n a l f o r Pa r a s I t o l o g y  33 (2003) 
that experience with hookworm infection does not confer 
resistance, except in a selected few individuals who some-
how acquire specific IgE responses against hookworm an-
tigens (Pritchard and Walsh, 1995; Pritchard et al., 1995). 
Susceptibility to reinfection was confirmed among volun-
teers who remained susceptible to hookworm reinfection 
even after infecting themselves with N. americanus (Max-
well et al., 1987). In support of the inability of the human 
host to mount natural immunity to Necator infection is the 
preliminary observation that hookworm antigens may in-
terfere with host lymphoproliferation and IL-4 levels dur-
ing chronic infections (J. M. Bethony and M. E. Bottazzi, 
unpublished observations). This might even be an active 
immunosuppressive process that occurs through hook-
worm-derived secreted antigens. Several investigators 
have isolated and characterized hookworm macromole-
cules that interfere with host cellular immune responses 
(Moyle et al., 1994; Culley et al., 2000).
3. Rationale for hookworm vaccine development
The steady increase of hookworm burdens as a function 
of age and the apparent absence of naturally acquired im-
munity in endemic areas have serious implications for na-
tional and international control efforts. The public health 
control of hookworm and other soil-transmitted helminths 
currently relies heavily on the use of benzimidazole an-
thelminthic drugs, especially albendazole (Albonico et 
al., 1999). However, studies sponsored by the WHO and 
other organizations have shown that high rates of hook-
worm reinfection can occur within just a few months fol-
lowing benzimidazole treatments (Albonico et al., 1995). 
Presumably because of the absence of acquired immunity 
following natural infection, treated individuals remain sus-
ceptible to reinfection following exposure to third-stage in-
fective hookworm larvae (L3) in the soil. This biological 
feature of the host–parasite relationship greatly limits the 
sustainability of anthelminthic chemotherapy-based con-
trol. In addition, most anthelminthic deworming programs 
worldwide currently target children in order to improve 
their physical growth, school performance, and cognitive 
development. While this approach might effectively, over 
time, reduce endemic exposure and worm burdens for As-
caris and Trichuris infections, there is no reason to believe 
that it would have an impact on endemic hookworm. It is 
therefore not surprising to discover that more than 1.2 bil-
lion individuals are infected with hookworms despite the 
widespread availability of albendazole.
An additional concern regarding the feasibility of sus-
tainable control with benzimidazoles is the possibility of 
emerging anthelminthic drug resistance among human 
hookworm populations. In some nematode species benz-
imidazole resistance occurs secondary to the spread of a 
single point mutation in nematode tubulin alleles. This 
phenomenon has already resulted in widespread benz-
imidazole resistance among soil-transmitted helminths of 
ruminant livestock in the Southern Hemisphere (Conder 
and Campbell, 1995), and might partially account for an 
observed failure of mebendazole chemotherapy for hu-
man hookworm in southern Mali (De Clercq et al., 1997).
The unique epidemiology of hookworms resulting 
from their apparent immunosuppressive properties, to-
gether with the potential for emerging anthelminthic re-
sistance, necessitates a search for alternative or comple-
mentary approaches to public health control that do not 
rely exclusively on anthelminthics. One approach for con-
sideration is the development and use of anti-hookworm 
vaccines.
4. Feasibility of hookworm vaccine development
Is it feasible to develop a vaccine for an infection in 
which natural experience with the pathogen does not con-
fer immunity? The concept of natural acquisition of immu-
nity was, after all, the cornerstone for the development of 
first-generation attenuated vaccines against poliomyeli-
tis, measles, and numerous other infections. A central chal-
lenge for hookworm vaccine development will be to stim-
ulate an artificial immune response that is unique and 
results in disease burden reduction. In this sense, an anti-
hookworm vaccine must overcome hurdles similar to those 
faced by vaccinologists who tackle HIV-AIDS and malaria.
Existing evidence that it is feasible to vaccinate against 
hookworms is based on three independent lines of re-
search (Hotez et al., 1996, 1999, in press):
1. Studies first conducted in the Department of Helmin-
thology at the Johns Hopkins School of Hygiene and 
Public Health during the 1930s in dogs and mice dem-
onstrated that artificial immunity against challenge 
infections with Ancylostoma caninum L3 could be ob-
tained by administering multiple inocula of living L3 
either orally or subcutaneously (McCoy, 1931, Foster, 
1935; Kerr, 1936; Otto and Kerr, 1939). The immunity 
conferred using multiple doses of living L3 was shown 
to be antibody mediated and could be administered 
passively (Otto, 1940, 1941). Typically, the immunity 
elicited by living L3 “vaccination” was not sterilizing 
but instead operated by reducing hookworm burdens 
relative to non-vaccinated control animals. The L3-vac-
cinated dogs were protected against hookworm dis-
ease characterized by heavy intestinal blood loss, but 
they were not protected against hookworm infection. 
Following very heavy challenge infections the mortal-
ity of severe hookworm disease was prevented by vac-
cination. Subsequent studies on the mechanisms of 
vaccine immunity demonstrated that host immune re-
sponses were directed primarily against the antigens 
secreted by L3 during host entry (Sarles, 1938; Talia-
ferro and Sarles, 1939; Sheldon and Groover, 1942).
2. Later, during the 1960s, the principles established by 
the development of living L3 vaccines were employed 
to develop an attenuated hookworm vaccine. This was 
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accomplished by first damaging A. caninum L3 with 
ionizing radiation, including X-rays, gamma-rays and 
ultraviolet light (Miller, 1971, 1978, 1987). The irradi-
ated L3 needed to remain viable in order for the vac-
cine to work—presumably viability was essential in 
order to ensure that the damaged L3 continued to se-
crete antigens after host entry. Ionizing radiation al-
lowed the vaccinator to increase the dose of L3 used in 
an inoculum thereby decreasing the number of doses 
required to achieve effective immunity. Ultimately, an 
attenuated canine hookworm vaccine was developed 
and marketed first in Florida and later in the Eastern 
United States during the early 1970s (Miller, 1978). 
The product soon failed commercially, however, be-
cause of its high production costs, limited shelf-life vi-
ability and inability on the part of both pet owner and 
veterinarian to appreciate how a vaccine that does 
not elicit sterilizing immunity (i.e., does not prevent 
against hookworm infection) is still useful for protect-
ing against hookworm disease.
3. Extracts of the esophagus of adult A. caninum elicit ac-
quired immunity (Thorson, 1956). This parasite or-
gan is enriched with proteases and much of the anti-
body in vaccinated dogs has the capacity to neutralize 
parasite protease activity (Thorson, 1956). These ef-
forts confirmed a prediction first made by Asa Chan-
dler during the 1930s that anti-enzyme antibodies have 
importance in mediating protective immunity against 
helminths (Chandler, 1932, 1936). More recently, stud-
ies conducted to develop a vaccine against Haemonchus 
contortus, a blood-feeding trichostrongyle nematode of 
sheep that is phylogenetically related to hookworms, 
identified the major antigens aligning the brush bor-
der membrane of the blood-feeding adult parasite al-
imentary canal (Knox, 2000). Among these antigens 
are parasite gut-derived glycoproteins that comprise 
a complex of proteases and other components (desig-
nated “H-gal-GP”), which bind to peanut lectin. Al-
though the H-gal-GP complex is not ordinarily rec-
ognized during natural infection, and is considered a 
hidden antigen, the complex when administered with 
a saponin-derived adjuvant (Quil A) elicits high levels 
of vaccine protection with respect to adult worm bur-
dens and fecundity (Knox and Smith, 2001).
To summarize, the feasibility of developing anti-hook-
worm vaccines is based on more than 70 years of success-
ful protection in laboratory animals, which is elicited ei-
ther by living L3 and their secreted antigens or by the 
antigens comprising the adult parasite alimentary canal.
5. Hookworm antigen discovery and selection
Hookworm antigens were selected as lead candidates 
for further testing on the basis of their link with either at-
tenuated larval vaccines or the H-gal-GP complex.
5.1. L3 secreted antigens
Progress on attenuated hookworm larval vaccines 
pointed to the importance of secreted L3 antigens as the 
major immunogenic macromolecules associated with 
vaccine protection. However, it was found that A. cani-
num L3 constitutively release only trace amounts of pro-
tein (Hawdon et al., 1995). A major breakthrough was 
the observation that L3, stimulated at 37 °C in the pres-
ence of a cocktail composed of an ultrafiltrate of canine 
serum and glutathione (or its derivatives), release com-
paratively large amounts of parasite-derived proteins 
(Hawdon and Hotez, 1996; Hawdon et al., 1995, 1996, 
1999; Zhan et al., 2002a). This observation made it possi-
ble to isolate the major secreted L3 antigens, obtain par-
tial amino acid sequences of the purified proteins, and 
subsequently clone and sequence their corresponding 
cDNAs.
5.1.1. Ancylostoma secreted proteins
The two most abundant gene products released by L3 
under host-stimulatory conditions are cysteine-rich se-
cretory proteins (CRISPs) belonging to the pathogenesis 
related protein (PRP) superfamily. The PRP superfamily 
is composed of a phylogenetically diverse array of ani-
mal and plant proteins including insect venom allergens, 
mammalian testis and epidydimal proteins, and plant-
pathogenesis related protein (Henriksen et al., 2001). The 
major L3 Ancylostoma secreted proteins (ASPs) are com-
posed of ASP-2 (Hawdon et al., 1999), a 24 kDa protein 
with a single PRP domain, and ASP-1 a 45 kDa double 
PRP domain protein corresponding to a heterodimorphic 
repeat (Hawdon et al., 1996). Isolation of approximately 
100 pmoles of each protein required the collection of up 
to 300,000 A. caninum L3, which were obtained by copro-
culture from the feces of infected donor dogs. This was 
followed by partial amino acid sequencing of the puri-
fied protein and then the synthesis of degenerate oligo-
nucleotides for cDNA library screening (Hawdon et al., 
1996, 1999). Orthologues of both asp-1 and asp-2 cDNAs 
were also subsequently isolated and cloned from A. duo-
denale, Ancylostoma ceylancium and N. americanus (Zhan et 
al., 1999). The orthologues exhibit high degrees of amino 
acid sequence similarity to each other. For instance, the N. 
americanus ASP-1 (Na-ASP-1) exhibits 97% identity to A. 
caninum ASP-1 (Ac-ASP-1).
The biological function of the ASPs is not known. 
One study conducted with an ASP orthologue from On-
chocerca volvulus suggests that it may exhibit angiogenic 
properties (Tawe et al., 2000). However, ASP orthologues 
are also present in the free-living nematode Caenorhabditis 
elegans and the plant pathogen Meloidogyne incognita, and 
therefore also presumably have a function that is unre-
lated to the host–parasite relationship. Adult hookworms 
also produce single and double domain ASPs, which im-
munolocalize to a number of different nematode organs 
including the cuticle, cephalic glands, and the brush bor-
der of the alimentary canal (Zhan et al., 2003).
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There are several lines of evidence that point to the 
ASPs as promising vaccine candidates: (1) Natural prod-
uct single and double domain ASPs were shown to pro-
tect sheep and guinea pigs against challenge infections 
with H. contortus (Kooyman et al., 2000; Sharp et al., 1992; 
Sharp and Wagland, 1998; Schallig et al., 1997a, 1997b, 
1997c). Vaccine protection relies on the presence of high 
levels of anti-ASP IgE (Kooyman et al., 2000). (2) Anti-
bodies obtained from the abomasal mucus and draining 
lymph nodes from calves immunized with multiple infec-
tions of Ostertagia ostertagi recognize an ASP orthologue 
(De Maere et al., 2002). In addition fractions of helminth 
antigens that protect cattle against O. ostertagi infection 
are enriched in single domain ASPs (Geldhof et al., 2003). 
(3) Vaccination of mice with a recombinant Escherichia coli 
fusion protein composed of a polyhistidine tag and amino 
acids 96–424 of either Ac-ASP-1 or Na-ASP-1 results in 
host immune responses, which inhibit the extra-intes-
tinal migration of A. caninum L3 into the lungs follow-
ing oral infection (Ghosh et al., 1996; Ghosh and Hotez, 
1999; Liu et al., 2000). Anti-Ac-ASP-1 antibody also pas-
sively protects against larval migration (Ghosh and Ho-
tez, 1999). (4) In two cross-sectional epidemiologic stud-
ies it was determined that residents of Hainan Province, 
China and Minas Gerais State, Brazil who harbor less in-
tense hookworm burdens (as measured by quantitative 
egg counts) exhibit high titers of circulating antibodies 
against a single domain ASP from L3 (Jeff Bethony, un-
published observation).
5.1.2. Astacin-like metalloprotease (MTP)
Hookworm L3 also releases a 62 kDa zinc metallopro-
tease upon host-stimulation (Zhan et al., 2002a). The MTP-
1 enzyme is of the astacin class represented by a metallo-
protease from the crayfish Astacus astacus. In addition to 
a catalytic domain composed of zinc in the enzyme active 
site coordinated by the imidazoles of conserved histidine 
residues, MTP-1 also contains an epidermal growth factor 
domain of unknown function. MTP-1 is an immunodom-
inant protein and was first cloned and isolated by screen-
ing an A. caninum cDNA expression library with pooled 
sera from hookworm-infected individuals who harbor 
low worm burdens and are putatively resistant (Zhan et 
al., 2002a). Calves immunized with O. ostertagi L3 also rec-
ognize an MTP-1 orthologue (De Maere et al., 2002). Stud-
ies examining the vaccine potential of Ac-MTP-1 from A. 
caninum are under evaluation, as is an orthologue from 
Ancylostoma ceylanicum (see below).
5.1.3. Other L3 antigens
In addition to the ASPs and MTP-1, Ancylostoma L3 
also releases macromolecules with amino acid similari-
ties to a 60 kDa acetylcholinesterase (ACH) and a 16 kDa 
(144 amino acids) putative transthyreitin (TTR), which 
may bind retinol binding proteins (Hawdon et al., un-
published). Previously, a secreted acetylcholinesterase 
has shown promise as a vaccine target against Dictyocau-
lus viviparous (McKeand, 2000) and Trichostrongylus col-
ubriformis (Griffiths and Pritchard, 1994). Each of these 
proteins is being evaluated as vaccine candidates, as is a 
hookworm L3 surface protein similar to Ov-103 from O. 
volvulus.
5.2. Adult hookworm antigens
5.2.1. Secreted antigens
There is no evidence that the excretory–secretory pro-
teins released by adult hookworms elicit high levels of 
vaccine protection. The major protein secreted by adult 
hookworms is TMP, a 16 kDa orthologue of mammalian 
tissue inhibitor of metalloprotease (Zhan et al., 2002b). Ac-
TMP comprises almost 10% of the protein secreted in vi-
tro by adult A. caninum (Zhan et al., 2002b). The function 
of this molecule for adult hookworms at the site of attach-
ment in the mammalian intestine is unknown. However, 
of interest is the observation that regions of amino acid 
sequence similarity between Ac-TMP and mammalian 
TIMPs are not those predicted to be in contact with their 
target matrix metalloproteases (Zhan et al., 2002b). This 
suggests the possibility that Ac-TMP has a function other 
than metalloprotease inhibition. In addition to TMP, adult 
A. caninum hookworms also release serine protease inhib-
itors including those involved in the coagulation cascade 
such as factor Xa (Cappello et al., 1995, 1996) and VIIa-tis-
sue factor (Stanssens et al., 1996), and some adult-specific 
ASPs (Zhan et al., in press).
5.2.2. H-gal-GP orthologues
The H-gal-GP complex from the brush border of the 
alimentary canal of H. contortus is composed of multiple 
components including a metalloendopeptidase of the ne-
prilysin family, an aspartic protease, a cysteinyl protease, 
a cystatin, a thrombospondin orthologue, and a galectin 
(Knox, 2000). As noted above, the complex elicits high lev-
els of protection against H. contortus challenge infections 
in sheep (Knox, 2000; Knox and Smith, 2001), although 
each component has so far not been examined individu-
ally as a natural product. Orthologues of each of the pro-
tease components of the complex have been cloned from 
hookworms including A. caninum-metalloendopeptidase-
1 (Ac-MEP-1) (Jones and Hotez, 2001), A. caninum-cyste-
inyl proteases (Ac-CP-1 and Ac-CP-2) (Harrop et al., 1995; 
Loukas et al., 2000), and A. caninum-aspartic proteases 
(Ac-APR-1 and Ac-APR-2) (Harrop et al., 1996; William-
son et al., 2002, 2003a, 2003b). Immunolocalization stud-
ies confirm that some of these proteases align the brush 
border membrane of the alimentary canal of adult hook-
worms ( Figure 3). These proteases are believed to oper-
ate in a coordinated fashion to facilitate host hemoglo-
bin degradation during blood feeding (Brinkworth et al., 
2000, 2001).
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6. The rules of engagement
Work conducted during the decade of the 1990s on H. con-
tortus vaccine protection experiments in sheep and A. cani-
num vaccine protection experiments in mice has provided 
some useful paradigms that might be applicable to preclini-
cal vaccine protection experiments in laboratory animals.
1. Many of the candidate vaccine antigens under evalua-
tion are hydrolytic enzymes, including proteases and 
acetylcholinesterases from L3 and adult stages. While 
the natural products isolated from parasites typi-
cally maintain their enzymatic activity, the activity is 
lost when the protease cDNAs are expressed in E. coli. 
Therefore, expression of bioactive molecules usually 
requires eukaryotic vectors.
2. Similarly, in instances where natural product antigens 
protect against challenge infections, the correspond-
ing recombinant protein expressed in E. coli fails to re-
produce the protection. In most cases this is because the 
conformational epitopes are lost during E. coli expres-
sion. Incorrect disulphide bond formation probably ac-
counts for most of the lost epitope expression, particu-
larly for cysteine-rich proteins like the ASPs, rather than 
the absence of correct glycosylation. The failure of E. coli 
to produce correctly folded antigens for vaccination was 
observed for L3 ASPs from H. contortus (Sharp and Wa-
gland, 1998) and A. caninum (see below), and for the H-
gal-GP complex components (Knox and Smith, 2001).
3. In some cases eukaryotic expression restores the con-
formational epitopes lost during E. coli expression. 
This has been demonstrated for baculovirus expressed 
ASP from H. contortus (Sharp and Wagland, 1998) and 
yeast-expressed Ac-ASP-1 (see below).
4. Among the eukaryotic vectors that have been em-
ployed to express candidate nematode vaccine anti-
gens are baculovirus, insect cells, and yeast. To date, 
it has not been possible to predict which vector system 
will work best. However, baculovirus and insect cells 
will likely prove to be too expensive for the manufac-
ture of a public sector hookworm vaccine. Leading the 
yeast expression vectors is the methanol-utilizing or-
ganism Pichia pastoris, which produces proteins in high 
yields and is relatively inexpensive compared to other 
eukaryotic expression systems.
5. In the few studies that have attempted to define the 
mechanisms associated with vaccine protection, achiev-
ing high levels of host antibody is required for reduc-
tion in worm burdens (Ghosh and Hotez, 1999). In some 
cases host IgE may be the principal effector antibody. 
This was suggested by the finding that low H. contor-
tus worm burdens in sheep associated with high levels 
of IgE directed H. contortus ASP (Kooyman et al., 2000). 
The importance of IgE antibody is also underscored by 
preliminary epidemiologic data suggesting that host 
IgE directed against ASP-2 was associated with reduced 
hookworm intensity, as determined by quantitative egg 
counts (Jeff Bethony, unpublished data).
6. Achieving high levels of host antibody using baculo-
virus, insect cell, or yeast-expressed proteins will be 
challenging, particularly when these proteins are for-
mulated with aluminum-based adjuvants such as alum 
or alhydrogel. The requirement for high levels of im-
munogenicity has prompted the search for alternative 
adjuvants.
7. Hookworm antigen expression
Over the last 2 years, focused efforts have been made 
to express the lead candidate antigens in both prokaryotic 
and eukaryotic systems (Table 1).
7.1. L3 hookworm antigens
Expression of Na-asp-1, Ac-asp-2, and Ac-mtp-1 cDNAs 
in E. coli has so far produced recombinant fusion proteins 
containing polyhistidine tags, which are neither soluble 
nor correctly refold in the absence of harsh denaturants, 
including ionic detergents. In addition, the E. coli recom-
binant fusion proteins frequently are expressed in inclu-
sion bodies that are heavily contaminated with other bac-
terial constituents. Frequently it is not possible to separate 
the recombinant fusion proteins away from these con-
taminants. In the case of the ASPs, the high number cys-
teines (10 in ASP-2 and 20 ASP-1) presumably cause re-
combinant polypeptides to form with aberrant disulphide 
bond formation. Recombinant E. coli Na-ASP-1 does not 
exhibit conformational epitopes corresponding to the na-
tive protein. As shown in Figure 4, polyclonal antibodies 
prepared against E. coli Na-ASP-1 fail to immunoprecipi-
tate the corresponding native protein from soluble L3 ex-
tracts. Similarly, recombinant Ac-MTP-1 expressed in E. 
Figure 3. Immunolocalization of Ac-MEP-1 (neprilysin-like adult 
hookworm metalloprotease) to the brush border membrane of the 
adult hookworm alimentary canal. 
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coli does not exhibit enzymatic activity. In order to over-
come these hurdles and express recombinant proteins ei-
ther having catalytic activity or appropriate conforma-
tional epitopes, their corresponding cDNAs had to be 
re-engineered in eukaryotic vectors, including baculovi-
rus, insect cells, or yeast. Polyclonal antibodies prepared 
against P. pastoris expressed Na-ASP-1 immunoprecip-
itate the native protein from soluble L3 extracts (Figure 
4). To date, the following L3 recombinant proteins have 
been successfully expressed in P. pastoris: Na-ASP-1, Na-
ASP-2, and Ac-TTR, from N. americanus and A. caninum, 
respectively, as well as Ay-ASP-1 and Ay-ASP-2, the or-
thologues from A. ceylanicum. One of the L3 acetylcholin-
esterases has also been expressed (M. Selkirk, personal 
communication). To date it has not been possible to ex-
press soluble Ac-MTP-1 and Ac-ASP-2 in yeast. However, 
Ac-ASP-2 as well as catalytically active Ac-MTP-1 was re-
cently expressed in baculovirus.
7.2. Adult hookworm antigens
Two of the small protease inhibitors released by adult 
A. caninum hookworms, Ac-TMP and Ac-AP (factor Xa 
inhibitor anticoagulant peptide) have been expressed as 
soluble recombinant fusion proteins in E. coli. However, 
none of the H-gal-GP orthologous proteases expressed in 
E. coli are soluble or exhibit enzymatic activity. Ac-MEP-
1, Ac-CP-1, a cysteinyl protease, and the aspartic prote-
ases, in contrast have been expressed as bioactive, soluble 
enzymes in either viral or non-viral insect cell expression 
systems (Loukas, Williamson, et al., unpublished). Ac-CP-
2 has been expressed in P. pastoris in biologically active 
form. Work is in progress to express the adult-stage-spe-
cific ASPs in eukaryotic systems (Zhan et al., in press).
8. Hookworm antigen-adjuvant formulation and 
vaccine testing
Two laboratory animal systems are now in routine use 
for preclinical vaccine development: hamsters challenged 
with L3 of A. ceylanicum and dogs challenged with L3 of 
A. caninum. An advantage of the hamster model is its rel-
atively low cost compared to dogs. In addition, hamsters 
infected with A. ceylanicum experience weight and blood 
loss similar to human disease from heavy infections (Bun-
giro et al., 2001). However, A. ceylanicum does not ordi-
narily cause intestinal blood loss in humans and the ham-
ster is not a natural host for the parasite. In addition, the 
number of adult hookworms that establish in hamsters 
is low—this requires the use of large numbers of ham-
sters in order to achieve adequate sample sizes for com-
paring experimental and control groups. In contrast, dogs 
are the natural hosts of A. caninum, and this model closely 
resembles A. duodenale hookworm infection. The abil-
ity to achieve high adult worm burdens in the laboratory 
Table 1. Lead candidate hookworm vaccine antigens
Antigen  Description  MW (kDa)  Expression vector
L3 secreted antigens
ASP-1  Pathogenesis-related protein  45  Pichia pastoris
ASP-2  Pathogenesis-related protein  24  P. pastoris and insect cell
MTP-1  Astacin metalloprotease  62  Baculovirus
TTR  Transthyreitin  16  Escherichia coli and P. pastoris
ACH  Acetylcholinesterase  60  P. pastoris
Adult gut-membrane antigens (H-gal-orthologues)
MEP-1  Neprilysin metalloprotease  99  Insect cells
APR-2  Aspartic protease  45  Baculovirus
CP-1  Cysteinyl protease  35  Insect cells and P. pastoris
CP-2  Cysteinyl protease  35  P. pastoris
ASP-5  Pathogenesis-related protein  24  P. pastoris (pending)
Figure 4. Immunoprecipitation of Ac-ASP-1 from biotinylated extracts 
of A. caninum L3. B, protein bound to strepavidin resin (immunopre-
cipitated). U, protein unbound to strepavidin resin (non-immuno-
precipitated). Group A, canine antiserum to two doses of irradiated 
A. caninum L3. Group B, canine antiserum to alum (adjuvant con-
trol). Group C, canine antiserum to Na-ASP-1 expressed in Pichia pas-
toris and administered with alum in four doses separated by 3 weeks. 
Group D, canine antiserum to Na-ASP-1 expressed in Pichia pastoris 
and administered with alum in four doses on days 1, 4, 60, and 64. 
Group E, canine antiserum to Na-ASP-1 expressed in Escherichia coli 
and administered with alum in four doses on days 1, 4, 60, and 64. 
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reduces the sample size required for comparing experi-
mental and control groups. For vaccine studies, purpose-
bred beagles are usually vaccinated with hookworm anti-
gens formulated with adjuvants beginning at 8–10 weeks 
of age. Up to 2 months are usually required to complete 
the immunization series, followed by challenge infections 
(Hotez et al., 2002).
In addition to the two Ancylostoma systems under in-
vestigation, some efforts have been made to adapt N. 
americanus to laboratory hamsters. Recently, Xiao Shuhua 
and his colleagues adapted N. americanus by passing it 
through 100 generations in a Chinese strain of the golden 
hamster (Xue et al., in press). By doing so, they have obvi-
ated the requirement for exogenous steroids and can ob-
tain reasonable levels of adult hookworm burdens by in-
fecting hamsters at 9–10 weeks of age. In contrast, other 
investigators have had to rely on infecting neonatal ham-
sters (Behnke and Pritchard, 1987).
To date, studies in dogs and hamsters have revealed that 
E. coli recombinant fusion proteins are more immunogenic 
than recombinant proteins expressed in baculovirus, insect 
cells, or yeast. Shown in Figure 5 is a direct comparison of 
pre-challenge antibody titers in dogs (five per group) vac-
cinated either with E. coli Na-ASP-1 or P. pastoris Na-ASP-1 
formulated with alhydrogel. The former exhibits far higher 
IgG2 antibody titers, although the IgG1 and IgE responses 
are similar. However, it is not clear whether the IgG2 re-
sponses might be directed against bacterial lipopolysac-
charide or E. coli protein contaminants. As noted above 
(Figure 4), many of the peptide sequences recognized by 
canine anti-E. coli-Na-ASP-1 do not correspond to confor-
mational epitopes on the native protein.
The comparatively low immunogenicity of eukary-
otic recombinant hookworm antigens formulated with 
aluminum-based adjuvants (e.g., alum and alhydrogel) 
points out a new requirement to explore alternative ad-
juvants. Among those under investigation, are oil–water 
emulsions such as montanide ISA-720 (Seppic) and ASO3 
(GlaxoSmithKline), as well as adjuvants containing sa-
ponin derivatives such as ASO2 (GlaxoSmithKline) and 
Quil A. ASO2 is an oil–water emulsion that contains QS-
21 (derived from saponin) and a lipid A derivative. Both 
ISA-720 and ASO2 have been used successfully in human 
clinical trials (Bojang et al., 2001; Doherty et al., 1999).
The importance of eliciting strong immune responses 
against the candidate recombinant hookworm antigens 
is highlighted by studies, which examine the relation-
ship between antibody titers and hookworm burdens. As 
shown in Figure 6, high levels of antigen-specific IgE di-
rected against recombinant E. coli Na-ASP-1 and Ac-TTR 
inversely correlate with hookworm burdens. In the case 
of E. coli Ac-MTP-1, the inverse relationship between anti-
body titer and worm burden is best correlated with IgG2 
(Figure 6). Because many of these antibodies directed 
against these E. coli proteins probably do not recognize 
conformational epitopes, the levels of vaccine protec-
tion should improve significantly by employing recom-
binant antigens expressed in eukaryotic systems. Also of 
great promise is the exploitation of new platform technol-
ogies for the development of anti-hookworm vaccines, in-
cluding the use of hepatitis B core particles for the expres-
sion of peptide epitopes from candidate vaccine antigens 
(Birkett et al., 2002). Among them are amino acids 291–
303 of Na-ASP-1, which correspond to a predicted hydro-
philic loop in the native molecule.
To summarize, each of the lead antigens has been ex-
pressed in eukaryotic vectors and is now under evalua-
tion as candidate vaccines in one or more of three differ-
ent laboratory animal challenge models (A. caninum in 
dogs, A. ceylanicum in hamsters and N. americanus in ham-
sters). Results from these studies will provide the basis 
for up-selection leading to process development and pi-
lot manufacture.
9. Future prospects
Even after process development and pilot manufacture 
is completed, however, there are still a number of hurdles 
that must be overcome before an anti-hookworm vaccine 
is produced for the developing world. Among them are 
the following.
Figure 5. Comparison of antigen-specific IgG1, IgG2, and IgE canine antibody titers in purpose-bred beagle dogs (n = 5 per group) vaccinated with 
150 μg of Escherichia coli Na-ASP-1 (four doses) or Pichia pastoris Na-ASP-1 (four doses using two different schedules). An additional group of dogs 
(n = 5) was vaccinated with A. caninum irradiated L3 (two doses). 
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1. No human clinical trials have ever been conducted with 
a recombinant nematode vaccine.
2. Preliminary studies conducted in Brazil suggest that 
patients chronically infected with hookworm are func-
tionally immunosuppressed and do not develop lym-
phoproliferative responses to hookworm antigens 
(J. Bethony and M. E. Bottazzi, unpublished observa-
tions). However, some patients who are treated for 
hookworm with anthelminthic drugs acquire a re-
newed capacity to respond to hookworm antigens. 
This suggests that human anti-hookworm vaccinations 
may need to be preceded by an initial round of anthel-
minthic treatment.
3. Little is known on the role of cross reactivity and reg-
ulation of the immune response in individuals carry-
ing more than a single helminthic infection, or its cor-
relation with the development of resistance to infection 
and reinfection.
4. If the requirement to develop IgE responses against 
some of the lead candidate hookworm vaccine anti-
gens is confirmed, then it may become necessary to 
choose adjuvant formulations and doses designed to 
enhance allergic-type responses. This could contribute 
to the vaccine’s ultimate toxicity.
5. Many of the hookworm antigens selected for further 
development contain partial amino acid sequences 
that are homologous with mammalian proteins. The 
potential for cross reactivity to autoantigens require 
investigation.
6. Hookworm is a disease of the “poorest of the poor” in 
the developing nations of the tropics. For this reason, 
there is practically no commercial market for an anti-
hookworm vaccine. The institutions for developing 
and manufacturing public sector vaccines are still ru-
dimentary. This is particularly unfortunate, given that 
the next generation of vaccines for diseases in devel-
oping countries, e.g., hookworm, HIV-AIDS, malaria, 
will require high levels of technological sophistication 
(Hotez, 2001; Broder et al., 2002).
7. Immunity to hookworm vaccines must be long-lasting 
in order to protect at-risk individuals exposed to hook-
worm L3 in adulthood.
8. The geographic variation of the candidate hookworm 
antigen amino acid sequences is largely unknown. 
However, preliminary studies with Na-ASP-1 indicate 
that for this particular antigen, geographic variation is 
not significant (J. Hawdon, unpublished observation).
Despite these obstacles, the potential impact of devel-
oping a hookworm vaccine is huge. Because of its contri-
bution to the burden of disease caused by iron deficiency 
anemia, hookworm is arguably the most significant hu-
man helminth pathogen worldwide. Its possible role in 
promoting increased susceptibility to other intercurrent 
pathogens, including HIV-AIDS will ensure hookworm’s 
disease burden impact.
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